{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:39:46Z","timestamp":1792003186857,"version":"4.4.0"},"reference-count":171,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Diabetic kidney disease (DKD) is one of the most serious complications of diabetes and the leading cause of end-stage renal disease worldwide. Recently, renin-angiotensin system inhibitors, non-steroidal mineralocorticoid receptor antagonists, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists were proposed as the four pillars for treating DKD. To understand the molecular mechanisms by which these drugs improve DKD, we described the histological and molecular changes due to diabetes. Based on our understanding of the molecular changes in DKD, we present evidence on the efficacy of these drugs in improving DKD and discuss why such drugs improve the prognosis of DKD. In addition to diabetes and hypertension, insulin resistance, dyslipidemia and hyperuricemia are risk factors for DKD. Metformin, fibrates, and febuxostat have been reported to improve DKD; however, caution is required when administering these drugs to patients with renal impairment due to concerns about the onset of lactic acidosis, rhabdomyolysis, and deterioration of renal function, respectively. Imeglimin, pemafibrate, and dotinurad have similar chemical structures or effects to metformin, fibrates, and febuxostat, respectively, but are safer in patients with renal impairment. Furthermore, they have specific mechanisms to improve DKD and may offer new options for its treatment. This article is a narrative review. Regarding emerging therapies for DKD, no high-evidence-level research has yet been published, and further progress in this area is warranted.<\/jats:p>","DOI":"10.3390\/ijms27062757","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:14:14Z","timestamp":1773832454000},"page":"2757","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Molecular Mechanisms and Clinical Evidence Supporting the Four Pillars of Therapy in Diabetic Kidney Disease: Emerging Therapeutic Perspectives"],"prefix":"10.3390","volume":"27","author":[{"given":"Hidekatsu","family":"Yanai","sequence":"first","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, National Kohnodai Medical Center, Japan Institute for Health Security, 1-7-1 Kohnodai, Ichikawa 272-8516, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, National Kohnodai Medical Center, Japan Institute for Health Security, 1-7-1 Kohnodai, Ichikawa 272-8516, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Hakoshima","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, National Kohnodai Medical Center, Japan Institute for Health Security, 1-7-1 Kohnodai, Ichikawa 272-8516, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayuki","family":"Katsuyama","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, National Kohnodai Medical Center, Japan Institute for Health Security, 1-7-1 Kohnodai, Ichikawa 272-8516, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2025). Standards of care in diabetes\u20142025. Diabetes Care, 48, S1\u2013S344.","DOI":"10.2337\/dc25-in01"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-9841-8_1","article-title":"Diabetic Nephropathy: An Overview","volume":"2067","author":"Sagoo","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"(2022). Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int., 102, S1\u2013S127.","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.cegh.2020.05.016","article-title":"Diabetic kidney disease: An overview of prevalence, risk factors, and biomarkers","volume":"9","author":"Hussain","year":"2021","journal-title":"Clin. Epidemiol. Glob. Health"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Wang, N., and Zhang, C. (2024). Oxidative Stress: A Culprit in the Progression of Diabetic Kidney Disease. Antioxidants, 13.","DOI":"10.3390\/antiox13040455"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial","volume":"376","author":"Craven","year":"2010","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wagnew, F., Eshetie, S., Kibret, G.D., Zegeye, A., Dessie, G., Mulugeta, H., and Alemu, A. (2018). Diabetic nephropathy and hypertension in diabetes patients of sub-Saharan countries: A systematic review and meta-analysis. BMC Res. Notes, 11.","DOI":"10.1186\/s13104-018-3670-5"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1681\/ASN.2006111199","article-title":"A population-based, prospective study of blood pressure and risk for end-stage renal disease in China","volume":"18","author":"Reynolds","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wudu, M.A., Birhanu, T.A., Tegegne, K.D., and Wondifraw, E.B. (2025). Incidence and predictors of diabetic kidney disease among type 2 diabetes mellitus adult patients in Ethiopia: A systematic review and meta-analysis. BMC Endocr. Disord., 25.","DOI":"10.1186\/s12902-025-02006-y"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/acph-2025-0002","article-title":"The impact of blood lipids and statins on renal function and mortality in patients with diabetic nephropathy: A meta-analysis","volume":"75","author":"Tian","year":"2025","journal-title":"Acta. Pharm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000516391","article-title":"Meta-Analysis of the Relationship between Abdominal Obesity and Diabetic Kidney Disease in Type 2 Diabetic Patients","volume":"14","author":"Zhao","year":"2021","journal-title":"Obes. Facts"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"538","DOI":"10.12998\/wjcc.v12.i3.538","article-title":"Impact of body mass index on adverse kidney events in diabetes mellitus patients: A systematic-review and meta-analysis","volume":"12","author":"Wan","year":"2024","journal-title":"World J. Clin. Cases"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.tips.2011.07.006","article-title":"The renin-angiotensin-aldosterone system and glucose homeostasis","volume":"32","author":"Luther","year":"2011","journal-title":"Trends. Pharmacol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.mcna.2009.02.014","article-title":"The renin angiotensin aldosterone system in hypertension: Roles of insulin resistance and oxidative stress","volume":"93","author":"Manrique","year":"2009","journal-title":"Med. Clin. N. Am."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1152\/physiol.00037.2016","article-title":"The Link Between Adipose Tissue Renin-Angiotensin-Aldosterone System Signaling and Obesity-Associated Hypertension","volume":"32","author":"Houben","year":"2017","journal-title":"Physiology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5049\/EBP.2024.22.2.21","article-title":"New Era in Diabetic Kidney Disease Treatment: The Four Pillars and Strategies to Build Beyond","volume":"22","author":"Han","year":"2024","journal-title":"Electrolytes Blood Press."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e280322202705","DOI":"10.2174\/1573399818666220328145046","article-title":"Histological Manifestations of Diabetic Kidney Disease and its Relationship with Insulin Resistance","volume":"19","year":"2023","journal-title":"Curr. Diabetes Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment","volume":"28","author":"Tonneijck","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jfma.2018.02.007","article-title":"Update of pathophysiology and management of diabetic kidney disease","volume":"117","author":"Lin","year":"2018","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"844","DOI":"10.14740\/jocmr2760w","article-title":"Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys","volume":"8","author":"Sano","year":"2016","journal-title":"J. Clin. Med. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1507\/endocrj.EJ22-0352","article-title":"The effect of arteriosclerosis on new-onset renal damage in diabetic patients","volume":"70","author":"Gao","year":"2023","journal-title":"Endocr. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1479164121992524","DOI":"10.1177\/1479164121992524","article-title":"Vascular inflammation, atherosclerosis, and lipid metabolism and the occurrence of non-high albuminuria diabetic kidney disease: A cross-sectional study","volume":"18","author":"Yang","year":"2021","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13036-022-00299-4","article-title":"Pathophysiology of mesangial expansion in diabetic nephropathy: Mesangial structure, glomerular biomechanics, and biochemical signaling and regulation","volume":"16","author":"Thomas","year":"2022","journal-title":"J. Biol. Eng."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1564847","DOI":"10.3389\/fcell.2025.1564847","article-title":"Podocytes in health and glomerular disease","volume":"13","author":"Cunanan","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Demirci, H. (2025). Glomerular alteration in diabetic kidney disease: From morphology to metabolism. Kidney Res. Clin. Pract., Online ahead of print.","DOI":"10.23876\/j.krcp.24.294"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"832887","DOI":"10.3389\/fcell.2022.832887","article-title":"Podocyte Injury in Diabetic Kidney Disease: A Focus on Mitochondrial Dysfunction","volume":"10","author":"Liu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"696542","DOI":"10.3389\/fcell.2021.696542","article-title":"Signaling Pathways Involved in Diabetic Renal Fibrosis","volume":"9","author":"Zhang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1238927","DOI":"10.3389\/fendo.2023.1238927","article-title":"Tubular injury in diabetic kidney disease: Molecular mechanisms and potential therapeutic perspectives","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Endocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ma, T., Li, X., Zhu, Y., Yu, S., Liu, T., Zhang, X., Chen, D., Du, S., Chen, T., and Chen, S. (2022). Excessive Activation of Notch Signaling in Macrophages Promote Kidney Inflammation, Fibrosis, and Necroptosis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.835879"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1161\/HYPERTENSIONAHA.107.107268","article-title":"The collecting duct is the major source of prorenin in diabetes","volume":"51","author":"Kang","year":"2008","journal-title":"Hypertension"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/14703203241302966","article-title":"Overview of the renin-angiotensin system in diabetic nephropathy","volume":"25","author":"Karimi","year":"2024","journal-title":"J. Renin-Angiotensin Aldosterone Syst."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/HYPERTENSIONAHA.119.12873","article-title":"Urinary Renin in Patients and Mice with Diabetic Kidney Disease","volume":"74","author":"Tang","year":"2019","journal-title":"Hypertension"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Leite, A.P.O., Li, X.C., Nwia, S.M., Hassan, R., and Zhuo, J.L. (2022). Angiotensin II and AT1a Receptors in the Proximal Tubules of the Kidney: New Roles in Blood Pressure Control and Hypertension. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052402"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1053\/ajkd.2000.16192","article-title":"Angiotensin II and its receptors in the diabetic kidney","volume":"36","author":"Burns","year":"2000","journal-title":"Am. J. Kidney Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1089\/ars.2009.2831","article-title":"Angiotensin II type 1 receptor-dependent oxidative stress mediates endothelial dysfunction in type 2 diabetic mice","volume":"13","author":"Wong","year":"2010","journal-title":"Antioxid. Redox Signal."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"F1187","DOI":"10.1152\/ajprenal.00653.2011","article-title":"Vascular smooth muscle function of renal glomerular and interlobar arteries predicts renal damage in rats","volume":"303","author":"Vavrinec","year":"2012","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"154890","DOI":"10.1016\/j.metabol.2021.154890","article-title":"Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies","volume":"124","author":"Ricciardi","year":"2021","journal-title":"Metabolism"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"F614","DOI":"10.1152\/ajprenal.00285.2012","article-title":"Angiotensin II contributes to glomerular hyperfiltration in diabetic rats independently of adenosine type I receptors","volume":"304","author":"Patinha","year":"2013","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.kisu.2021.11.004","article-title":"Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease","volume":"12","author":"Nakamura","year":"2022","journal-title":"Kidney Int. Suppl."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/j.ajkd.2022.04.016","article-title":"Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms","volume":"80","author":"Epstein","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/nm.1879","article-title":"Modification of mineralocorticoid receptor function by Rac1 GTPase: Implication in proteinuric kidney disease","volume":"14","author":"Shibata","year":"2008","journal-title":"Nat. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/hr.2016.137","article-title":"Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension","volume":"40","author":"Shibata","year":"2017","journal-title":"Hypertens. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1254\/jphs.10R07CR","article-title":"Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney","volume":"115","author":"Rafiq","year":"2011","journal-title":"J. Pharmacol. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41581-020-0309-2","article-title":"Autophagy in kidney homeostasis and disease","volume":"16","author":"Tang","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s11255-019-02074-9","article-title":"Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes","volume":"51","author":"Dong","year":"2019","journal-title":"Int. Urol. Nephrol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"F556","DOI":"10.1152\/ajprenal.00332.2016","article-title":"NLRP3 inflammasome activation contributes to aldosterone-induced podocyte injury","volume":"312","author":"Bai","year":"2017","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_49","first-page":"4589","article-title":"Aldosterone is involved in the pathogenesis of obesity-related glomerulopathy through activation of Wnt\/\u03b2-catenin signaling in podocytes","volume":"17","author":"Zhu","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_50","first-page":"97","article-title":"The endothelial mineralocorticoid receptor: Mediator of the switch from vascular health to disease","volume":"26","author":"Davel","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1161\/CIRCRESAHA.108.174235","article-title":"Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion","volume":"102","author":"Caprio","year":"2008","journal-title":"Circ. Res."},{"key":"ref_52","first-page":"329","article-title":"Spironolactone inhibits NADPH oxidase-induced oxidative stress and enhances eNOS in human endothelial cells","volume":"10","author":"Taye","year":"2011","journal-title":"Iran. J. Pharm. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1210\/en.2007-0864","article-title":"Aldosterone induces superoxide generation via Rac1 activation in endothelial cells","volume":"149","author":"Iwashima","year":"2008","journal-title":"Endocrinology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/01.HYP.0000226054.53527.bb","article-title":"Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity","volume":"48","author":"Nagata","year":"2006","journal-title":"Hypertension"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.kisu.2021.11.006","article-title":"The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis","volume":"12","author":"Luther","year":"2022","journal-title":"Kidney Int. Suppl."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/CIRCRESAHA.122.321335","article-title":"Kidney Tubular IL-1\u03b2 ENaCtivation in Diabetes and Salt-Sensitive Hypertension","volume":"131","author":"Pitzer","year":"2022","journal-title":"Circ. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"13396","DOI":"10.1096\/fj.202000966RR","article-title":"NOX4-dependent regulation of ENaC in hypertension and diabetic kidney disease","volume":"34","author":"Pavlov","year":"2020","journal-title":"FASEB J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI41080","article-title":"Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice","volume":"120","author":"Usher","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/path.2259","article-title":"Macrophage involvement in the kidney repair phase after ischaemia\/reperfusion injury","volume":"214","author":"Vinuesa","year":"2008","journal-title":"J. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling","volume":"93","author":"Estrela","year":"2018","journal-title":"Kidney Int."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/ndt\/gfy246","article-title":"Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation","volume":"34","author":"Rocha","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.gene.2013.08.047","article-title":"Aldosterone stimulates fibronectin synthesis in renal fibroblasts through mineralocorticoid receptor-dependent and independent mechanisms","volume":"531","author":"Chen","year":"2013","journal-title":"Gene"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1113\/JP277002","article-title":"RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition","volume":"597","author":"Koszegi","year":"2019","journal-title":"J. Physiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"100893","DOI":"10.1016\/j.cophys.2025.100893","article-title":"Emerging Roles for Endothelial Mineralocorticoid Receptor in Disease Pathogenesis: Potential New Indications for MR Antagonism","volume":"47","author":"An","year":"2025","journal-title":"Curr. Opin. Physiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.2174\/1381612811319170009","article-title":"Angiotensin II blockade and renal protection","volume":"19","author":"Kobori","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Currie, G., Taylor, A.H., Fujita, T., Ohtsu, H., Lindhardt, M., Rossing, P., Boesby, L., Edwards, N.C., Ferro, C.J., and Townend, J.N. (2016). Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: A systematic review and meta-analysis. BMC Nephrol., 17.","DOI":"10.1186\/s12882-016-0337-0"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone\u2019s Antifibrotic Activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of Finerenone on Albuminuria in Patients with Diabetic Nephropathy: A Randomized Clinical Trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s41440-022-00913-4","article-title":"Aldosterone breakthrough from a pharmacological perspective","volume":"45","author":"Mogi","year":"2022","journal-title":"Hypertens. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1152\/physrev.00031.2005","article-title":"Adenosine and kidney function","volume":"86","author":"Vallon","year":"2006","journal-title":"Physiol. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1681\/ASN.V10122569","article-title":"Glomerular hyperfiltration in experimental diabetes mellitus: Potential role of tubular reabsorption","volume":"10","author":"Vallon","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","article-title":"Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat","volume":"302","author":"Thomson","year":"2012","journal-title":"Am. J. Physiol.-Regul. Integr. Comp. Physiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Wie","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"178","DOI":"10.14740\/jocmr2857w","article-title":"A Possible Mechanism for Renoprotective Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Elevation of Erythropoietin Production","volume":"9","author":"Yanai","year":"2017","journal-title":"J. Clin. Med. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejphar.2009.03.065","article-title":"Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat","volume":"612","author":"Toba","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1159\/000319653","article-title":"Erythropoietin protects podocytes from damage by advanced glycation end-products","volume":"117","author":"Ruester","year":"2011","journal-title":"Nephron Exp. Nephrol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"F911","DOI":"10.1152\/ajprenal.00643.2012","article-title":"Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db\/db mouse","volume":"305","author":"Loeffler","year":"2013","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_88","first-page":"581","article-title":"Hyperuricemia Predicts the Progression of Type 2 Diabetic Kidney Disease in Chinese Patients","volume":"14","author":"Zhu","year":"2023","journal-title":"Diabetes Ther."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Yanai, H., Adachi, H., Hakoshima, M., and Katsuyama, H. (2021). Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179221"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Li, S., Sanna, S., Maschio, A., Busonero, F., Usala, G., Mulas, A., Lai, S., Dei, M., Orr\u00f9, M., and Albai, G. (2007). The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet., 3.","DOI":"10.1371\/journal.pgen.0030194"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/ng.106","article-title":"SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout","volume":"40","author":"Vitart","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5ra11","DOI":"10.1126\/scitranslmed.3000237","article-title":"Common defects of ABCG2, a high-capacity urate exporter, cause gout: A function-based genetic analysis in a Japanese population","volume":"1","author":"Matsuo","year":"2009","journal-title":"Sci. Transl. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"7520632","DOI":"10.1155\/2022\/7520632","article-title":"Impacts of Sodium\/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis","volume":"2022","author":"Akbari","year":"2022","journal-title":"J. Diabetes Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1111\/dom.15157","article-title":"Serum uric acid lowering and effects of sodium-glucose cotransporter-2 inhibitors on gout: A meta-analysis and meta-regression of randomized controlled trials","volume":"25","author":"Banerjee","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3390\/gucdd2020014","article-title":"SGLT2 Inhibitors and uric acid homeostasis","volume":"2","author":"Zapf","year":"2024","journal-title":"Gout Urate Cryst. Depos. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1159\/000545131","article-title":"Sodium-glucose cotransporter 2 inhibitors and uric acid","volume":"149","author":"Lanaspa","year":"2025","journal-title":"Nephron"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1161\/CIRCULATIONAHA.123.065517","article-title":"Metabolic communication by SGLT2 inhibition","volume":"149","author":"Billing","year":"2024","journal-title":"Circulation"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2215\/CJN.11480821","article-title":"SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function","volume":"17","author":"Suijk","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/dom.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7150\/ijbs.33007","article-title":"Empagliflozin Attenuates Hyperuricemia by Upregulation of ABCG2 via AMPK\/AKT\/CREB Signaling Pathway in Type 2 Diabetic Mice","volume":"16","author":"Lu","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1038\/s41598-019-41253-7","article-title":"Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells","volume":"9","author":"Maki","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2337\/db15-0473","article-title":"Impaired Podocyte Autophagy Exacerbates Proteinuria in Diabetic Nephropathy","volume":"65","author":"Tagawa","year":"2016","journal-title":"Diabetes"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/ard-2023-224242","article-title":"SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy","volume":"82","author":"Zhao","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e83353","DOI":"10.7554\/eLife.83353","article-title":"Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome","volume":"12","author":"Ge","year":"2023","journal-title":"Elife"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/ndt\/gfab330","article-title":"Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob\/ob mice","volume":"37","author":"Hudkins","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nrm3440","article-title":"Endoplasmic reticulum-mitochondria contacts: Function of the junction","volume":"13","author":"Rowland","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"113512","DOI":"10.1016\/j.yexcr.2023.113512","article-title":"Mitochondria-associated endoplasmic reticulum membranes promote mitochondrial fission through AKAP1-Drp1 pathway in podocytes under high glucose conditions","volume":"424","author":"Li","year":"2023","journal-title":"Exp. Cell Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"154182","DOI":"10.1016\/j.metabol.2020.154182","article-title":"Activation of TRPV1 channel antagonizes diabetic nephropathy through inhibiting endoplasmic reticulum-mitochondria contact in podocytes","volume":"105","author":"Wei","year":"2020","journal-title":"Metabolism"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","article-title":"Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission","volume":"15","author":"Zhou","year":"2018","journal-title":"Redox. Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/s41401-021-00805-2","article-title":"Dapagliflozin attenuates pressure overload-induced myocardial remodeling in mice via activating SIRT1 and inhibiting endoplasmic reticulum stress","volume":"43","author":"Ren","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s12964-024-01914-1","article-title":"Inhibition of SGLT2 protects podocytes in diabetic kidney disease by rebalancing mitochondria-associated endoplasmic reticulum membranes","volume":"22","author":"Li","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrneph.2010.152","article-title":"Endothelial dysfunction as a potential contributor in diabetic nephropathy","volume":"7","author":"Nakagawa","year":"2011","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Yanai, H., Adachi, H., Hakoshima, M., and Katsuyama, H. (2023). Significance of Endothelial Dysfunction Amelioration for Sodium-Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney Disease in Diabetic Patients. Metabolites, 13.","DOI":"10.20944\/preprints202305.0041.v1"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and Renal Outcomes in Type 2 Diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_117","first-page":"1248","article-title":"MicroRNA-770-5p is involved in the development of diabetic nephropathy through regulating podocyte apoptosis by targeting TP53 regulated inhibitor of apoptosis 1","volume":"23","author":"Zhang","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3109\/10799893.2015.1101137","article-title":"CD2-associated protein participates in podocyte apoptosis via PI3K\/Akt signaling pathway","volume":"36","author":"Ren","year":"2016","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bbrc.2023.04.012","article-title":"GLP-1 receptor agonist, liraglutide, protects podocytes from apoptosis in diabetic nephropathy by promoting white fat browning","volume":"664","author":"Wang","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: Mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00467-018-4005-4","article-title":"Oxidative stress in chronic kidney disease","volume":"34","author":"Daenen","year":"2019","journal-title":"Pediatr. Nephrol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/s41598-025-85658-z","article-title":"Exploring Liraglutide\u2019s mechanism in reducing renal fibrosis: The Fsp1-CoQ10-NAD(P)H pathway","volume":"15","author":"Chen","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"136","DOI":"10.23876\/j.krcp.22.001","article-title":"GLP-1 receptor agonists in diabetic kidney disease: Current evidence and future directions","volume":"41","author":"Yu","year":"2022","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"F1647","DOI":"10.1152\/ajprenal.00082.2009","article-title":"Regulation of Na+\/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells","volume":"297","author":"Malnic","year":"2009","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"11486","DOI":"10.1038\/s41598-025-95673-9","article-title":"Glucagon like peptide-1 modulates urinary sodium excretion in diabetic kidney disease via ENaC activation","volume":"15","author":"Kodama","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e70098","DOI":"10.1111\/nep.70098","article-title":"Mitigating Lipotoxicity: A Potential Mechanism to Delay Chronic Kidney Disease Progression Using Current Pharmacological Therapies","volume":"30","author":"Anumas","year":"2025","journal-title":"Nephrology"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Yanai, H., Adachi, H., Hakoshima, M., Iida, S., and Katsuyama, H. (2023). Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202309.1062.v1"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Park, M.J., Han, H.J., and Kim, D.I. (2017). Lipotoxicity-Induced PRMT1 Exacerbates Mesangial Cell Apoptosis via Endoplasmic Reticulum Stress. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071421"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.abb.2015.08.009","article-title":"Metformin ameliorates lipotoxicity-induced mesangial cell apoptosis partly via upregulation of glucagon like peptide-1 receptor (GLP-1R)","volume":"584","author":"Kim","year":"2015","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.14740\/cr1459","article-title":"Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients with Type 2 Diabetes","volume":"14","author":"Yanai","year":"2023","journal-title":"Cardiol. Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3803\/EnM.2015.30.2.216","article-title":"Glucagon-like peptide-1 increases mitochondrial biogenesis and function in INS-1 rat insulinoma cells","volume":"30","author":"Kang","year":"2015","journal-title":"Endocrinol. Metab."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1657274","DOI":"10.3389\/fmed.2025.1657274","article-title":"Evaluation of febuxostat in treating diabetic kidney disease with hyperuricemia: A systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Lin","year":"2025","journal-title":"Front. Med."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Lim, Y.J., Sidor, N.A., Tonial, N.C., Che, A., and Urquhart, B.L. (2021). Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets. Toxins, 13.","DOI":"10.3390\/toxins13020142"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"11147","DOI":"10.1038\/s41598-018-29208-w","article-title":"Identification of ABCG2 as an Exporter of Uremic Toxin Indoxyl Sulfate in Mice and as a Crucial Factor Influencing CKD Progression","volume":"8","author":"Takada","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3389\/fphar.2016.00518","article-title":"Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations","volume":"7","author":"Miyata","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.1038\/s41598-021-86662-9","article-title":"Hypouricemic agents reduce indoxyl sulfate excretion by inhibiting the renal transporters OAT1\/3 and ABCG2","volume":"11","author":"Taniguchi","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/jpet.119.259341","article-title":"Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor","volume":"371","author":"Taniguchi","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Yanai, H., Katsuyama, H., Hakoshima, M., and Adachi, H. (2023). Urate Transporter 1 Can Be a Therapeutic Target Molecule for Chronic Kidney Disease and Diabetic Kidney Disease: A Retrospective Longitudinal Study. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020567"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s10157-023-02419-w","article-title":"Efficacy of dotinurad in patients with severe renal dysfunction","volume":"28","author":"Kurihara","year":"2024","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"8990","DOI":"10.1038\/s41598-025-94020-2","article-title":"Comparative assessment of the effects of dotinurad and febuxostat on the renal function in chronic kidney disease patients with hyperuricemia","volume":"15","author":"Takata","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1655502","DOI":"10.3389\/fendo.2025.1655502","article-title":"Switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, may substantially reduce serum urate levels, through URAT1 inhibition, potentially without adversely affecting ABCG2 function: Findings from the SWITCH SURI study","volume":"16","author":"Osonoi","year":"2025","journal-title":"Front. Endocrinol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Yanai, H., Adachi, H., Hakoshima, M., and Katsuyama, H. (2023). Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications. Biology, 12.","DOI":"10.3390\/biology12050726"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"100106","DOI":"10.1016\/j.pharmr.2025.100106","article-title":"Metformin-mechanisms of its glycemia-reducing effect","volume":"78","author":"Drewe","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1210\/clinem\/dgae477","article-title":"Renal Protective Effect of Metformin in Type 2 Diabetes Patients","volume":"110","author":"Wang","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Lin, Y.L., Lin, S.H., Wang, H.H., Hsu, W.C., Hung, S.Y., Chiou, Y.Y., Liou, H.H., Chang, M.Y., Ho, L.C., and Wu, C.F. (2025). Role of Metformin in Preventing New-Onset Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus. Pharmaceuticals, 18.","DOI":"10.3390\/ph18010095"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"8742","DOI":"10.18632\/aging.103095","article-title":"Metformin: The updated protective property in kidney disease","volume":"12","author":"Pan","year":"2020","journal-title":"Aging"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1002\/jcp.26505","article-title":"Metformin attenuates folic-acid induced renal fibrosis in mice","volume":"233","author":"Yi","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Hallakou-Bozec, S., Kergoat, M., Fouqueray, P., Bolze, S., and Moller, D.E. (2021). Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0241651"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","article-title":"Metformin-associated lactic acidosis: Current perspectives on causes and risk","volume":"65","author":"DeFronzo","year":"2016","journal-title":"Metabolism"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e15151","DOI":"10.14814\/phy2.15151","article-title":"Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin","volume":"10","author":"Theurey","year":"2022","journal-title":"Physiol. Rep."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature13270","article-title":"Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase","volume":"510","author":"Madiraju","year":"2014","journal-title":"Nature"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nrendo.2017.80","article-title":"Regulation of hepatic glucose metabolism in health and disease","volume":"13","author":"Petersen","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e00128","DOI":"10.1002\/edm2.128","article-title":"Short-and long-term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome","volume":"3","author":"Lachaux","year":"2020","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_154","first-page":"1301","article-title":"Imeglimin in Patients with an Estimated Glomerular Filtration Rate Less than 45 mL\/min per 1.73 m(2): A Case Series","volume":"8","author":"Fukunaga","year":"2025","journal-title":"JMA J."},{"key":"ref_155","first-page":"e66322","article-title":"Imeglimin for Type 2 Diabetes Mellitus: Its Efficacy and Insight Into the Potential Benefit for Renal and Liver Function","volume":"16","author":"Uto","year":"2024","journal-title":"Cureus"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41598-023-27689-y","article-title":"Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes","volume":"13","author":"Hozumi","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1133352","DOI":"10.3389\/fneph.2023.1133352","article-title":"Insulin and the kidneys: A contemporary view on the molecular basis","volume":"3","year":"2023","journal-title":"Front. Nephrol."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Migdalis, I.N., Ioannidis, I.M., Papanas, N., Raptis, A.E., Sotiropoulos, A.E., and Dimitriadis, G.D. (2022). Hypertriglyceridemia and Other Risk Factors of Chronic Kidney Disease in Type 2 Diabetes: A Hospital-Based Clinic Population in Greece. J. Clin. Med., 11.","DOI":"10.3390\/jcm11113224"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12944-026-02862-0","article-title":"Hypertriglyceridemia in chronic kidney disease: Pathophysiological mechanisms, cardiovascular risk, and emerging therapeutics","volume":"25","author":"Li","year":"2026","journal-title":"Lipids Health Dis."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.2337\/dc16-1246","article-title":"Plasma Triglycerides and HDL-C Levels Predict the Development of Diabetic Kidney Disease in Subjects with Type 2 Diabetes: The AMD Annals Initiative","volume":"39","author":"Russo","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1503711","DOI":"10.3389\/fendo.2025.1503711","article-title":"Lipid abnormality in diabetic kidney disease and potential treatment advancements","volume":"16","author":"Tu","year":"2025","journal-title":"Front. Endocrinol."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Yanai, H., Adachi, H., Hakoshima, M., and Katsuyama, H. (2022). Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073418"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000381190","article-title":"Renoprotective Effects of Fenofibrate via Modulation of LKB1\/AMPK mRNA Expression and Endothelial Dysfunction in a Rat Model of Diabetic Nephropathy","volume":"95","author":"Attia","year":"2015","journal-title":"Pharmacology"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00228-009-0723-7","article-title":"Rhabdomyolysis associated with fibrate therapy: Review of 76 published cases and a new case report","volume":"65","author":"Wu","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12933-019-0864-7","article-title":"The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM\u03b1) paradigm: Conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation","volume":"18","author":"Fruchart","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Aomura, D., Harada, M., Yamada, Y., Nakajima, T., Hashimoto, K., Tanaka, N., and Kamijo, Y. (2021). Pemafibrate Protects against Fatty Acid-Induced Nephropathy by Maintaining Renal Fatty Acid Metabolism. Metabolites, 11.","DOI":"10.3390\/metabo11060372"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"121590","DOI":"10.1016\/j.lfs.2023.121590","article-title":"Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease","volume":"321","author":"Horinouchi","year":"2023","journal-title":"Life Sci."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2169\/internalmedicine.49.2597","article-title":"Effect of fenofibrate on uric acid metabolism and urate transporter 1","volume":"49","author":"Uetake","year":"2010","journal-title":"Intern. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"358","DOI":"10.14740\/cr1333","article-title":"Significant Increase of Estimated Glomerular Filtration Rate After Switching from Fenofibrate to Pemafibrate in Type 2 Diabetic Patients","volume":"12","author":"Yanai","year":"2021","journal-title":"Cardiol. Res."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4093\/dmj.2023.0370","article-title":"Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease","volume":"48","author":"Izumihara","year":"2024","journal-title":"Diabetes Metab. J."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/6\/2757\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:16:04Z","timestamp":1773832564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/6\/2757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":171,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ijms27062757"],"URL":"https:\/\/doi.org\/10.3390\/ijms27062757","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]}}}